Membrane androgen receptors (OXER1, GPRC6A AND ZIP9) in prostate and breast cancer: A comparative study of their expression.


Journal

Steroids
ISSN: 1878-5867
Titre abrégé: Steroids
Pays: United States
ID NLM: 0404536

Informations de publication

Date de publication:
02 2019
Historique:
received: 14 01 2019
accepted: 24 01 2019
pubmed: 2 2 2019
medline: 7 6 2019
entrez: 2 2 2019
Statut: ppublish

Résumé

Accumulating evidence during the last decades revealed that androgens exert membrane-initiated actions leading to the modulation of significant cellular processes, important for cancer cell growth and metastasis (including prostate and breast), that involve signaling via specific kinases. Collectively, many nonclassical, cell surface-initiated androgen actions are mediated by novel membrane androgen receptors (mARs), unrelated to nuclear androgen receptors. Recently, our group identified the G protein coupled oxo-eicosanoid receptor 1 (OXER1) (a receptor of the arachidonic acid metabolite, 5-oxoeicosatetraenoic acid, 5-oxoETE) as a novel mAR involved in the rapid effects of androgens. However, two other membrane proteins, G protein-coupled receptor family C group 6 member A (GPRC6A) and zinc transporter member 9 (ZIP9) have also been portrayed as mARs, related to the extranuclear action of androgens. In the present work, we present a comparative study of in silico pharmacology, gene expression and immunocytochemical data of the three receptors in various prostate and breast cancer cell lines. Furthermore, we analyzed the immunohistochemical expression of these receptors in human tumor and non-tumoral specimens and provide a pattern of expression and intracellular distribution.

Identifiants

pubmed: 30707908
pii: S0039-128X(19)30008-X
doi: 10.1016/j.steroids.2019.01.006
pii:
doi:

Substances chimiques

Cation Transport Proteins 0
GPRC6A protein, human 0
OXER1 protein, human 0
Receptors, Eicosanoid 0
Receptors, G-Protein-Coupled 0
Slc39a9 protein, human 0

Types de publication

Comparative Study Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

100-108

Informations de copyright

Copyright © 2019 Elsevier Inc. All rights reserved.

Auteurs

Konstantina Kalyvianaki (K)

Laboratory of Experimental Endocrinology, University of Crete, School of Medicine, Heraklion 71013, Greece.

Athanasios A Panagiotopoulos (AA)

Laboratory of Experimental Endocrinology, University of Crete, School of Medicine, Heraklion 71013, Greece.

Panagiotis Malamos (P)

Laboratory of Experimental Endocrinology, University of Crete, School of Medicine, Heraklion 71013, Greece.

Eleni Moustou (E)

Laboratory of Pathology, University of Crete, School of Medicine, Heraklion 71013, Greece.

Maria Tzardi (M)

Laboratory of Pathology, University of Crete, School of Medicine, Heraklion 71013, Greece.

Efstathios N Stathopoulos (EN)

Laboratory of Pathology, University of Crete, School of Medicine, Heraklion 71013, Greece.

Georgios S Ioannidis (GS)

Foundation for Research and Technology - Hellas (FORTH), Institute of Computer Science (ICS), Computational Bio-Medicine Laboratory (CBML), Heraklion, Greece.

Kostas Marias (K)

Foundation for Research and Technology - Hellas (FORTH), Institute of Computer Science (ICS), Computational Bio-Medicine Laboratory (CBML), Heraklion, Greece; Technological Educational Institute of Crete, Department of Informatics Engineering, Heraklion, Greece.

George Notas (G)

Laboratory of Experimental Endocrinology, University of Crete, School of Medicine, Heraklion 71013, Greece.

Panayiotis A Theodoropoulos (PA)

Laboratory of Biochemistry, University of Crete, School of Medicine, Heraklion 71013, Greece.

Elias Castanas (E)

Laboratory of Experimental Endocrinology, University of Crete, School of Medicine, Heraklion 71013, Greece. Electronic address: castanas@uoc.gr.

Marilena Kampa (M)

Laboratory of Experimental Endocrinology, University of Crete, School of Medicine, Heraklion 71013, Greece. Electronic address: kampam@uoc.gr.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH